Diversified Trust Co Grows Stock Holdings in Vericel Corporation $VCEL

Diversified Trust Co boosted its holdings in Vericel Corporation (NASDAQ:VCEL) by 70.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,061 shares of the biotechnology company’s stock after buying an additional 4,585 shares during the period. Diversified Trust Co’s holdings in Vericel were worth $471,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. State of Wyoming grew its stake in Vericel by 3.8% in the 1st quarter. State of Wyoming now owns 10,428 shares of the biotechnology company’s stock valued at $465,000 after buying an additional 381 shares in the last quarter. Portside Wealth Group LLC grew its stake in Vericel by 9.9% in the 1st quarter. Portside Wealth Group LLC now owns 6,546 shares of the biotechnology company’s stock valued at $292,000 after buying an additional 591 shares in the last quarter. CW Advisors LLC grew its stake in Vericel by 0.3% in the 1st quarter. CW Advisors LLC now owns 182,866 shares of the biotechnology company’s stock valued at $8,159,000 after buying an additional 593 shares in the last quarter. US Bancorp DE grew its stake in Vericel by 29.9% in the 1st quarter. US Bancorp DE now owns 3,071 shares of the biotechnology company’s stock valued at $137,000 after buying an additional 706 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in Vericel by 34.8% in the 1st quarter. GAMMA Investing LLC now owns 2,895 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 748 shares in the last quarter.

Vericel Stock Down 1.9%

Vericel stock opened at $31.21 on Wednesday. The company has a market capitalization of $1.57 billion, a PE ratio of 260.11 and a beta of 1.33. The firm has a fifty day simple moving average of $35.54 and a two-hundred day simple moving average of $39.96. Vericel Corporation has a twelve month low of $29.93 and a twelve month high of $63.00.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings results on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.03. The business had revenue of $63.24 million during the quarter, compared to the consensus estimate of $64.61 million. Vericel had a net margin of 2.85% and a return on equity of 2.47%. The firm’s revenue for the quarter was up 20.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.10) earnings per share. As a group, equities analysts expect that Vericel Corporation will post 0.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Stephens restated an “overweight” rating and set a $67.00 price target on shares of Vericel in a research report on Monday, June 16th. Canaccord Genuity Group reduced their price target on shares of Vericel from $61.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, August 1st. Finally, BTIG Research lowered shares of Vericel from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 17th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $60.40.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.